Skip to main content
. 2021 Sep 29;12:706027. doi: 10.3389/fimmu.2021.706027

Figure 1.

Figure 1

CXCL10 expression is increased in chronic prostatitis patients and experimental autoimmune prostatitis (EAP) mice. (A) CXCL10 expression in the serum of chronic prostatitis patients and healthy volunteers. (B) CXCL10 expression in the serum of chronic prostatitis patients with and without pain symptom. (C) Pearson’s correlation coefficient analysis for CXCL10 expression and National Institutes of Health Chronic Prostatitis Symptom Index. (D) The diagnostic efficiency of CXCL10 expression in the serum for chronic prostatitis patients. The expression levels of CXCL10 in prostate (E) and serum (F) of EAP mice. (G) RT-qPCR was used to assess CXCL9, CXCL10, CXCL11, and CXCR3 expressions in prostate from EAP mice. (H) IHC staining for CXCL10 and CXCR3 in prostate from EAP mice. Quantification of IHC staining of CXCL10 (I) and CXCR3 (J) in prostate from EAP mice. Data are shown as mean ± standard deviation (SD) by one-way ANOVA analysis (B), or unpaired, two-tailed Student’s t-test analysis (A, E, F, G, I, J), or Pearson’s correlation (C). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.